Related Experiment Videos

Crry, but not CD59 and DAF, is indispensable for murine erythrocyte protection in vivo from spontaneous complement

Takashi Miwa1, Lin Zhou, Brendan Hilliard

  • 1Center for Experimental Therapeutics and Department of Pharmacology, University of Pennsylvania School of Medicine, Philadelphia 19104, USA.

Blood
|May 3, 2002
PubMed

Insights

Mice lacking decay-accelerating factor (DAF) or CD59 on erythrocytes did not develop anemia. Complement receptor 1 (CR1)-related gene y (Crry) was essential for preventing complement-mediated erythrocyte destruction in mice.

Area of Science:

  • Immunology
  • Complement System
  • Hematology

Background:

  • Decay-accelerating factor (DAF) and CD59 are membrane proteins that regulate complement activation.
  • CD59 deficiency in humans causes erythrocyte sensitivity to complement lysis, suggesting its critical role.
  • The in vivo roles of DAF and CD59 in erythrocytes remain to be fully elucidated.

Purpose of the Study:

  • To investigate the in vivo significance of CD59 and DAF in protecting erythrocytes from complement attack.
  • To compare the roles of CD59, DAF, and complement receptor 1 (CR1)-related gene y (Crry) in murine erythrocyte protection.

Main Methods:

  • Generation and analysis of CD59 knockout and CD59/DAF double-knockout mice.
  • Assessment of erythrocyte sensitivity to complement lysis in vitro.
  • Evaluation of erythrocyte lifespan and complement deposition in vivo.
  • Study of Crry-deficient mouse erythrocytes.

Main Results:

  • CD59-deficient and CD59/DAF-double-deficient mouse erythrocytes showed high sensitivity to antibody-induced complement lysis in vitro.
  • Neither CD59 knockout nor CD59/DAF double-knockout mice developed spontaneous hemolytic anemia, and their erythrocytes had normal in vivo lifespan.
  • Crry-deficient erythrocytes were rapidly cleared from circulation, exhibiting increased spontaneous C3 deposition compared to DAF-deficient erythrocytes.

Conclusions:

  • CD59 and DAF are not essential for protecting murine erythrocytes from spontaneous complement attack.
  • Crry, a C3 inhibitor, is crucial for regulating complement activation on mouse erythrocytes.
  • CR1, not DAF, may be the primary regulator of spontaneous C3 activation on human erythrocytes.

Related Concept Videos